Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abnova (Taiwan)TPE:4133 +1.46%77 EV-to-EBIT is 469.68 as of Aug. 20, 2026, which is 1214% above its 10-year median of 35.74. GuruFocus rates TPE:4133 with a GF Score™ of 77/100 and a GF Value™ of NT$27.85 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 368 Biotechnology companies, Abnova (Taiwan) ranks worse than 98.64% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Abnova (Taiwan)'s Enterprise Value for the quarter that ended in Mar. 2026 was NT$986.0 Mil.
Abnova (Taiwan)'s EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) EV-to-EBIT Related Terms
Abnova (Taiwan) EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s EV-to-EBIT falls into.
Abnova (Taiwan)'s current Enterprise Value is NT$868.0 Mil.
Abnova (Taiwan)'s EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a EV-to-EBIT of 469.68 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Abnova (Taiwan) and its competitors. This is 1214% above median its historical median of 35.74. According to the industry distribution chart, Abnova (Taiwan) ranks #363 out of 368 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Abnova (Taiwan)'s EV-to-EBIT too high?
Abnova (Taiwan)'s current EV-to-EBIT of 469.68 is 1214% above median its 10-year median of 35.74. The Biotechnology industry median EV-to-EBIT is 16.63. Abnova (Taiwan)'s value of 469.68 is 2724.3% above this industry median. Based on the distribution chart, Abnova (Taiwan) ranks #363 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abnova (Taiwan) has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #363 out of 368 companies for EV-to-EBIT. This places Abnova (Taiwan) in the lower half of its industry. The industry median EV-to-EBIT is 16.63. Abnova (Taiwan)'s value of 469.68 is 2724.3% above this benchmark. While the company's 10-year median is 35.74 vs. the industry median of 16.63, Abnova (Taiwan) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.63, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abnova (Taiwan)'s current EV-to-EBIT of 469.68 is 2724.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Abnova (Taiwan) and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abnova (Taiwan)'s current EV-to-EBIT is 469.68, which is 1214% above median its own 10-year median of 35.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.85, compared to a current price of NT$20.85 — trading 25.1% below its estimated fair value. The current EV-to-EBIT is 469.68, which is 1214% above median its 10-year median of 35.74 and 2724.3% above the Biotechnology industry median of 16.63. Abnova (Taiwan)'s overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current EV-to-EBIT is 469.68 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.85 is trading 25.1% below its estimated GF Value™ of NT$27.85.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
EV-to-EBIT: 469.68 (1214% above median its 10-year median of 35.74)
GF Value™: NT$27.85 vs. price of NT$20.85 (25.1% below fair value)
Industry Position: 2724.3% above the Biotechnology median (#363 of 368)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
77GF Score
Get the complete analysis for TPE:4133
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
